DEAR VISITORS, THE NEW WEBSITE IS UNDER CONSTRUCTION, SO WE ASK FOR YOUR UNDERSTANDING IF YOU ENCOUNTER OUT-OF-DATE OR INCORRECT INFORMATION. FOR ALL QUESTIONS, WE ARE AT YOUR DISPOSAL BY PHONE +38131597597 or e-mail address: office@cigota.rs
Srpski
English
Русский
The dapagliflozine-type 2 sodium glucose cotransporter inhibitor in the treatment of diabetes mellitus type 2
English
natasa.neskovic977@gmail.com, djenic.cigota@gmail.comHealth Center Uzice
Special Hospital for Thyroid and Metabolism Disorders Zlatibor
Đukić A, Đurđević P, Živančević-Simonović S, Jurišić V, Mijatović Lj. Opšta patološka fiziologija. Beograd; Intergraf: 2002; 400–408.
International Diabetes Federation. IDF Diabetes Atlas, 7th ed. International Diabetes Federation: Brussels, Belgium: 2015; available at: http://www.diabetesatlas.org
Stark Casagrande, S., Fradkin, J., Saydah, S., Rust, K. and Cowie, C. (2013) The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care 36: 2271–2279.
The dapagliflozine-type 2 sodium glucose cotransporter inhibitor in the treatment of diabetes mellitus type 2
| Attachment | Size |
|---|---|
 medicinski_glasnik_73_vidic_e.pdf | 226.63 KB |
CONTACT US